IBSA Institut Biochimique SA

IBSA Institut Biochimique SA is a Swiss pharmaceutical company headquartered in Massagno, in the Lugano area of the canton of Ticino. Founded in 1945 by three Swiss natural scientists, the company initially focused on the Swiss market. A management buy-out in 1985, a strategy of improving active substances through new dosage forms to enhance their application, therapeutic efficacy and tolerability, and international expansion drove a growth spurt from the 1990s onwards. New production facilities were opened, subsidiaries were established abroad, acquisitions were made, and new active substances and medicines were introduced. The company develops, produces and markets active substances and medicines in the fields of sterility treatment, rheumatology, sports medicine, dermatology and pneumology. It increasingly works on pharmacotherapeutic systems with complex mechanisms of action that require formulation-intensive dosage forms. IBSA has several sites in the Lugano area and subsidiaries in Italy, Slovakia, Turkey, Hungary and China, employing around 1,000 people. In 2006 it generated revenue of around 300 million Swiss francs. IBSA Switzerland offers innovative therapeutic solutions for well-being, including OTC products designed to improve daily health. Its product range includes Flector®, ialugen Plus® Akut, BioVigor®, Vitamina D3, Eisen, ialugen® Calm Gel & Spray, Hyaluxelle® Ovuli, syrel®, thirodium®, and Ferro IBSA as an innovative melt film. The company also addresses health topics such as arthrosis, knee arthrosis, erectile dysfunction, urological health, thyroid health, women's intimate health, sports injuries, winter ailments, skin problems, wound healing, acute pain, and important vitamins and minerals. In aesthetic medicine, IBSA develops innovative solutions for physicians and patients.

IBSA Institut Biochimique SA was founded in 1945 by three Swiss natural scientists and initially concentrated on the Swiss market. The company is headquartered in Massagno, in the Lugano area of the canton of Ticino. A management buy-out in 1985 marked a turning point. The company pursued a strategy of improving active substances through new dosage forms to enhance their application, therapeutic efficacy and tolerability. Combined with international expansion, this led to a growth spurt from the 1990s onwards. New production facilities were opened, subsidiaries were established abroad, acquisitions were made, and new active substances and medicines were introduced. By the mid-2000s, IBSA had several sites in the Lugano area and subsidiaries in Italy, Slovakia, Turkey, Hungary and China, employing around 1,000 people and generating revenue of around 300 million Swiss francs in 2006. The company continues to develop, produce and market active substances and medicines in sterility treatment, rheumatology, sports medicine, dermatology and pneumology, and increasingly works on pharmacotherapeutic systems with complex mechanisms of action requiring formulation-intensive dosage forms.

• 2006

  Generated revenue of around 300 million Swiss francs and employed around 1,000 people.

• 1990

  Start of a growth spurt driven by international expansion and a strategy of improving active substances through new dosage forms.

• 1985

  Management buy-out.

• 1945

  Founded by three Swiss natural scientists, initially focusing on the Swiss market.

Innovative therapeutic solutions for well-being, with a focus on formulation-intensive dosage forms and complex mechanisms of action.

• Flector®

  A product listed among IBSA Switzerland's offerings.

• ialugen Plus® Akut

  A product listed among IBSA Switzerland's offerings.

• BioVigor®

  A product listed among IBSA Switzerland's offerings.

• Vitamina D3

  Vitamin D3 contributes to normal immune system function and maintenance of normal bones.

• Eisen

  Iron contributes to the reduction of tiredness and fatigue.

• Ferro IBSA

  An innovative melt film containing iron.

• ialugen® Calm Gel & Spray

  A product listed among IBSA Switzerland's offerings.

• Hyaluxelle® Ovuli

  A product listed among IBSA Switzerland's offerings.

• syrel®

  A product listed among IBSA Switzerland's offerings.

• thirodium®

  A product listed among IBSA Switzerland's offerings.

1. 1IBSA Switzerlandpharma.ibsaswitzerland.ch
2. 2IBSA Institut Biochimiquede.wikipedia.org
3. 3Wikidata Q1653132wikidata.org